0001209191-20-057297.txt : 20201106
0001209191-20-057297.hdr.sgml : 20201106
20201106163855
ACCESSION NUMBER: 0001209191-20-057297
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201104
FILED AS OF DATE: 20201106
DATE AS OF CHANGE: 20201106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEONARD JOHN M
CENTRAL INDEX KEY: 0001563584
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 201294991
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS INC
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER NAME:
FORMER CONFORMED NAME: LEONARD JOHN M.
DATE OF NAME CHANGE: 20121204
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-04
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001563584
LEONARD JOHN M
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
1
1
0
0
President and CEO
Common Stock
2020-11-04
4
M
0
50000
6.83
A
517352
D
Common Stock
2020-11-04
4
S
0
50000
26.00
D
467352
D
Common Stock
58415
I
By Trust
Stock Option (right to buy)
6.83
2020-11-04
4
M
0
50000
0.00
D
2026-02-02
Common Stock
50000
275234
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Shares held by the John M. Leonard 2015 Irrevocable Trust.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020.
/s/Jose Rivera Attorney-In-Fact
2020-11-06